Navigation Links
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Date:3/13/2008

d of care in this patient setting."

The study was pre-published online in the journal, Haematologica. Data from the 60 patient Phase I/II trial conducted by the PETHEMA Foundation in Spain were evaluated by the stringent European Group for Blood and Marrow Transplantation (EBMT) criteria and results are as follows:

-- Results showed an immunofixation-negative CR rate of 32 percent and an

overall response rate (ORR) of 89 percent with VcMP.

-- The overall survival rate at 38 months was 85 percent with VcMP

compared to the 38 percent historical control with melphalan and

prednisone (MP) (p<0.0001). The median overall survival for VcMP has

not been reached compared to 26 months among the historical control

with MP.

-- The median time-to-disease progression (TTP) with VcMP of 27.2 months

compared to 20 months for the historical control with MP (p=0.001).

-- The median event-free survival (EFS) with VcMP of 25 months compared to

15 months for the historical control with MP (p=0.001).

-- VcMP was well tolerated in this elderly patient population (median age

of 75) with patients on therapy for more than nine months. The safety

profile was predictable and manageable.

Patients received VELCADE at 1.3 mg/m2 (n=54) or 1.0 mg/m2 (n=6) twice weekly in weeks one, two, four and five for four six-week cycles (eight doses per cycle), followed by once weekly in weeks one, two, three and four for five, five-week cycles (four doses per cycle) in combination with melphalan at 9 mg/m2 and prednisone at 60 mg/m2 once daily on days 1 through 4 of each cycle. Treatment continued for a maximum of 49 weeks (52 vials) with a median number of 39 weeks (42 vials) reported in the trial. The safety profile of VcMP was as expected based on the known safety profile of each of the individual agents in the combination, including thrombocytopenia, neutropenia and peripher
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products
2. New Legal Momentum Publication Exposes How Abstinence-Only Programs Harm Women and Girls
3. Fourth Annual James E. Marshall OCD Foundation Beyond Beauty Dinner to Honor E. Scott Beattie, Chairman and CEO, Elizabeth Arden, Inc. and Charles H. Townsend, President and CEO, Conde Nast Publications
4. Bojan M. Kuure Recognized by Strathmores Whos Who Worldwide Publication
5. Nature publication on pain research
6. CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation
7. Fry Construction Is Featured in Key Industry Publication
8. GSA confers 2007 Richard Kalish Innovative Publication Award to USCs Mather
9. Telemedicine publication expands coverage
10. Scientific Publications Strategy & Delivery Shifts from Marketing to Medical
11. Johnson & Johnson Tops Annual Pharmaceutical Company Rankings in a New Report From Industry-Leading Publication Scrip
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... 22, 2015 Four years since the release of ... coincided with the marriage of Avasa & Matthew Love – the ... is scheduled for release through White Swan Records on February 24, ... is a sacred path available to all of us to walk ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... when kidneys are damaged, study finds, , , WEDNESDAY, Jan. ... at a greater risk of heart failure, stroke and other ... University of Glasgow study of adults ages 70 to 82 ... a three times greater risk of having non-fatal heart failure ...
... synthetic chemical version of what male sea lampreys use ... and foil the mating process of the destructive invasive ... chemical scents used to attract a mate, are well-documented ... fisheries and wildlife, has focused much of his career ...
... 21 Erdman, A Cogdell,Spencer Company, a subsidiary of ... it broke ground earlier this week on two new ... feet. , The two projects, ... in Jackson, Tennessee and a $1.75 million cancer center ...
... Market Intelligence and Competitive Analysis from Thomson Reuters to ... and LONDON, Jan. 21 /PRNewswire/ -- Thomson ... businesses and professionals, has announced the availability of three ... July - September 2008. The quarterly Pharma Matters ...
... Calif., Jan. 21 Human Pheromone,Sciences, Inc. (OTC ... it has established a website devoted to its ... Company filed Comprehensive Patent,Applications with both the U.S. ... the World Patent Office. On the site, the ...
... the "hands down winner"SANTA FE, N.M., Jan. 21 ... best health information search engine by AltSearchEngines.com , ... Mednar (still in beta) debuted in November ... professional medical researchers. It enables users to quickly access ...
Cached Medicine News:Health News:Chemical come-on successfully lures lovesick lampreys to traps 2Health News:Cogdell Spencer Breaks Ground on Projects in Tennessee and North Carolina 2Health News:Cogdell Spencer Breaks Ground on Projects in Tennessee and North Carolina 3Health News:Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008 2Health News:Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008 3Health News:HPS Establishes Independent Website for its Patent-Pending Mood-Enhancing Compound Naturally Found in Sea Coral 2Health News:Deep Web Technologies' Mednar Is Rated the #1 Alternative Health Search Engine 2Health News:Deep Web Technologies' Mednar Is Rated the #1 Alternative Health Search Engine 3
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... CLEVELAND , Jan. 22, 2015  ViewRay™, a privately ... entered into an exclusive distributor agreement with ITOCHU Corporation ... radiation therapy system for the treatment of cancer in ... (me-rid-i-an) system, is the world,s first and only MRI-guided ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: